Glutamine in pediatrics: where next?
OBJECTIVE
We reviewed the literature and examined the issues surrounding the use of glutamine in pediatrics and neonatology.


METHODS
We reviewed the literature using Medline, Embase, Current Contents, and International Pharmaceutical Abstracts. Additional information was obtained from bibliographic citations and personal communications.


RESULTS
Evidence showed that glutamine levels are affected in a number of life stages and conditions. Useful, indicative studies are emerging but many fail to demonstrate significant differences. The problems of researching in this patient population were demonstrated.


CONCLUSIONS
A need for a great deal of further research in this area, including larger multicenter trials, clearly emerged.
Ball
Patrick A
PA
School of Pharmacy, Department of Clinical Pharmacy, University of Auckland, Building 504, 85 Park Road, Grafton, Auckland, New Zealand. p.ball@auckland.ac.nz
Hardy
Gil
G
D000367:Age Factors; D000818:Animals; D002648:Child; D002675:Child, Preschool; D019587:Dietary Supplements; D004064:Digestive System / Q000254:growth & development / Q000378:metabolism*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005973:Glutamine / Q000008:administration & dosage* / Q000378:metabolism / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D007230:Infant, Low Birth Weight; D007231:Infant, Newborn; D016239:MEDLINE; D009751:Nutritional Requirements; D016896:Treatment Outcome
D005973:Glutamine